Identification of potential clinical markers associated with prognosis of neuroblastoma
Open Access
- 24 February 2026
- journal article
- research article
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Abstract
Aim This study retrospectively analyzed the data of patients with neuroblastoma (NB) to explore the risk factors and independent risk factors affecting the prognosis of patients. Method A retrospective analysis was conducted on the data of patients with NB diagnosed and treated at Children’s Hospital of Kunming Medical University from January 2014 to December 2024. Kaplan–Meier (KM) survival analysis and the Cox Proportional Hazards Model were used to ascertain the risk factors and to identify independent risk factors associated with overall survival (OS) and disease-free survival (DFS), respectively. Result A total of 231 patients were retrospectively analyzed. The results of Cox Proportional Hazards Model showed that age, tumor volume of onset (TVO), LNF (lactate dehydrogenase-neuron specific enolase-ferritin), metastasis site, DNA ploidy, and recurrence were independent risk factors affecting the OS. TVO, lactate dehydrogenase (LDH), neuron specific enolase (NSE), ferritin, LNF, image-defined risk factors (IDRFs), metastasis site, and DNA ploidy were independent risk factors affecting the DFS of patients. Conclusion Reliable biomarkers are crucial for effective patient stratification and personalized treatment strategies for NB. Early identification of high-risk patients and the initiation of aggressive treatment can help improve OS and DFS in patients.Keywords
This publication has 35 references indexed in Scilit:
- C-reactive protein-to-lymphocyte ratio and hemoglobin-to-red cell distribution width ratio as effective prognostic predictors in pediatric patients with neuroblastomaEuropean Journal of Pediatrics, 2025
- Evaluation of Minimal Residual Disease in Patients with NeuroblastomaMolecular Diagnosis & Therapy, 2025
- Cellular morphometric biomarkers and large language model predict prognosis and treatment response in neuroblastoma patients: A retrospective and double-blind prospective single arm clinical studyEuropean Journal of Cancer, 2025
- Emerging Trends in Neuroblastoma Diagnosis, Therapeutics, and ResearchMolecular Neurobiology, 2025
- Metabolic targeting of neuroblastoma, an updateCancer Letters, 2024
- Advances and challenges in therapeutic resistant biomarkers of neuroblastoma: A comprehensive reviewBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024
- Association of image-defined risk factors with clinical features, tumor biology, and outcomes in neuroblastoma: a single-center retrospective studyEuropean Journal of Pediatrics, 2023
- Prognostic impact of tumor size on patients with neuroblastoma in a SEER‐based studyCancer Medicine, 2022
- NeuroblastomaPediatric Blood & Cancer, 2021
- Risk stratification of high‐risk metastatic neuroblastoma: A report from the HR‐NBL‐1/SIOPEN studyPediatric Blood & Cancer, 2018